| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tamoxifen | 105 | 2024 | 981 | 5.950 |
Why?
|
| Breast Neoplasms | 337 | 2024 | 20824 | 5.820 |
Why?
|
| Antineoplastic Agents, Hormonal | 86 | 2024 | 1524 | 4.420 |
Why?
|
| Chemotherapy, Adjuvant | 170 | 2024 | 3480 | 3.920 |
Why?
|
| Receptor, erbB-2 | 65 | 2024 | 2417 | 3.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 169 | 2023 | 11525 | 3.090 |
Why?
|
| Receptors, Estrogen | 86 | 2021 | 2190 | 2.620 |
Why?
|
| Nitriles | 35 | 2021 | 955 | 2.510 |
Why?
|
| Triazoles | 35 | 2021 | 908 | 2.400 |
Why?
|
| Disease-Free Survival | 115 | 2023 | 6896 | 1.810 |
Why?
|
| Antineoplastic Agents | 70 | 2022 | 13693 | 1.590 |
Why?
|
| Premenopause | 52 | 2024 | 1033 | 1.440 |
Why?
|
| Aromatase Inhibitors | 27 | 2023 | 490 | 1.400 |
Why?
|
| Receptors, Progesterone | 38 | 2021 | 1098 | 1.370 |
Why?
|
| Neoadjuvant Therapy | 14 | 2023 | 2727 | 1.270 |
Why?
|
| Clinical Trials as Topic | 62 | 2018 | 7914 | 1.240 |
Why?
|
| Meta-Analysis as Topic | 11 | 2018 | 1342 | 1.130 |
Why?
|
| Androstadienes | 9 | 2019 | 345 | 1.060 |
Why?
|
| Randomized Controlled Trials as Topic | 60 | 2024 | 9955 | 0.970 |
Why?
|
| Lymphatic Metastasis | 70 | 2020 | 2924 | 0.960 |
Why?
|
| Quality of Life | 61 | 2024 | 12802 | 0.940 |
Why?
|
| Mastectomy | 34 | 2021 | 1793 | 0.910 |
Why?
|
| Methotrexate | 63 | 2016 | 1728 | 0.870 |
Why?
|
| Cyclophosphamide | 59 | 2019 | 2242 | 0.840 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 38 | 2012 | 1520 | 0.820 |
Why?
|
| Neoplasm Recurrence, Local | 53 | 2023 | 9240 | 0.790 |
Why?
|
| Postmenopause | 41 | 2021 | 2460 | 0.770 |
Why?
|
| Fluorouracil | 59 | 2013 | 1619 | 0.770 |
Why?
|
| Female | 407 | 2024 | 380193 | 0.740 |
Why?
|
| Goserelin | 13 | 2019 | 129 | 0.740 |
Why?
|
| Ovary | 10 | 2019 | 981 | 0.730 |
Why?
|
| Neoplasms, Hormone-Dependent | 13 | 2018 | 415 | 0.730 |
Why?
|
| Treatment Outcome | 104 | 2022 | 63107 | 0.700 |
Why?
|
| Survival Analysis | 51 | 2021 | 10252 | 0.670 |
Why?
|
| Carcinoma, Lobular | 8 | 2021 | 484 | 0.650 |
Why?
|
| Doxorubicin | 35 | 2018 | 2234 | 0.620 |
Why?
|
| Humans | 475 | 2024 | 744366 | 0.590 |
Why?
|
| Models, Statistical | 13 | 2018 | 5101 | 0.580 |
Why?
|
| Statistics as Topic | 10 | 2018 | 2373 | 0.520 |
Why?
|
| Proportional Hazards Models | 38 | 2024 | 12356 | 0.520 |
Why?
|
| Drug Administration Schedule | 39 | 2019 | 4933 | 0.520 |
Why?
|
| Prognosis | 100 | 2023 | 29060 | 0.510 |
Why?
|
| Mastectomy, Segmental | 11 | 2018 | 956 | 0.500 |
Why?
|
| Survival Rate | 61 | 2021 | 12788 | 0.490 |
Why?
|
| Ki-67 Antigen | 10 | 2015 | 644 | 0.470 |
Why?
|
| Data Interpretation, Statistical | 12 | 2016 | 2716 | 0.470 |
Why?
|
| Lymph Nodes | 21 | 2019 | 3476 | 0.460 |
Why?
|
| Carcinoma, Ductal, Breast | 12 | 2018 | 1100 | 0.440 |
Why?
|
| Combined Modality Therapy | 64 | 2024 | 8642 | 0.430 |
Why?
|
| Neoplasms | 20 | 2024 | 21696 | 0.430 |
Why?
|
| Quality-Adjusted Life Years | 9 | 2012 | 1683 | 0.420 |
Why?
|
| Phthalazines | 3 | 2024 | 363 | 0.410 |
Why?
|
| Estrogen Receptor alpha | 5 | 2020 | 577 | 0.400 |
Why?
|
| Middle Aged | 173 | 2023 | 213390 | 0.400 |
Why?
|
| Research Design | 15 | 2017 | 5984 | 0.400 |
Why?
|
| Infectious Disease Transmission, Vertical | 7 | 2007 | 1320 | 0.400 |
Why?
|
| Follow-Up Studies | 84 | 2022 | 39052 | 0.380 |
Why?
|
| Estrogen Antagonists | 7 | 2012 | 152 | 0.380 |
Why?
|
| Amenorrhea | 12 | 2019 | 485 | 0.370 |
Why?
|
| Pregnancy Complications, Infectious | 10 | 2007 | 2026 | 0.360 |
Why?
|
| Adult | 151 | 2023 | 214052 | 0.360 |
Why?
|
| Neoplasm Staging | 36 | 2023 | 11031 | 0.350 |
Why?
|
| Prednisone | 23 | 2003 | 1574 | 0.330 |
Why?
|
| Aged | 126 | 2021 | 163288 | 0.320 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2019 | 841 | 0.320 |
Why?
|
| Double-Blind Method | 30 | 2021 | 12025 | 0.300 |
Why?
|
| Lymph Node Excision | 7 | 2018 | 1262 | 0.300 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 2018 | 255 | 0.290 |
Why?
|
| Multicenter Studies as Topic | 13 | 2019 | 1677 | 0.280 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2019 | 115 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 11 | 2011 | 9274 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2020 | 6539 | 0.280 |
Why?
|
| Radiotherapy, Adjuvant | 13 | 2018 | 1771 | 0.270 |
Why?
|
| Ovariectomy | 11 | 2019 | 661 | 0.270 |
Why?
|
| Menopause | 18 | 2010 | 1626 | 0.270 |
Why?
|
| Antibiotics, Antineoplastic | 8 | 2013 | 692 | 0.260 |
Why?
|
| Pregnancy Outcome | 6 | 2019 | 2795 | 0.250 |
Why?
|
| Immunotherapy | 8 | 2022 | 4446 | 0.250 |
Why?
|
| Taxoids | 6 | 2019 | 666 | 0.240 |
Why?
|
| Diphosphonates | 1 | 2009 | 623 | 0.240 |
Why?
|
| Cranial Irradiation | 7 | 2006 | 401 | 0.240 |
Why?
|
| Zidovudine | 6 | 1996 | 620 | 0.230 |
Why?
|
| Drug Approval | 2 | 2022 | 742 | 0.220 |
Why?
|
| Imidazoles | 1 | 2009 | 1206 | 0.220 |
Why?
|
| Consensus | 2 | 2024 | 2960 | 0.210 |
Why?
|
| Piperazines | 2 | 2024 | 2488 | 0.210 |
Why?
|
| Markov Chains | 1 | 2005 | 969 | 0.200 |
Why?
|
| Quinazolines | 4 | 2015 | 1356 | 0.200 |
Why?
|
| Models, Psychological | 1 | 2005 | 811 | 0.190 |
Why?
|
| Paclitaxel | 4 | 2021 | 1708 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2013 | 895 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 8 | 2018 | 1062 | 0.170 |
Why?
|
| Age Factors | 19 | 2020 | 18373 | 0.170 |
Why?
|
| Withholding Treatment | 3 | 2023 | 599 | 0.170 |
Why?
|
| Immunohistochemistry | 18 | 2014 | 11366 | 0.160 |
Why?
|
| Nevirapine | 4 | 2004 | 267 | 0.160 |
Why?
|
| Immunity | 2 | 2022 | 1014 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2018 | 323 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2021 | 350 | 0.160 |
Why?
|
| Axilla | 10 | 2018 | 597 | 0.160 |
Why?
|
| Neoplasm Metastasis | 11 | 2019 | 4851 | 0.160 |
Why?
|
| Toremifene | 3 | 2008 | 24 | 0.150 |
Why?
|
| Menopause, Premature | 1 | 2019 | 132 | 0.150 |
Why?
|
| HIV Infections | 12 | 2007 | 16715 | 0.150 |
Why?
|
| Sample Size | 2 | 2018 | 845 | 0.150 |
Why?
|
| Time Factors | 43 | 2019 | 40075 | 0.150 |
Why?
|
| Proto-Oncogenes | 2 | 1997 | 321 | 0.150 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2011 | 129 | 0.150 |
Why?
|
| Fetus | 1 | 2004 | 1880 | 0.150 |
Why?
|
| Pregnancy | 22 | 2023 | 29144 | 0.140 |
Why?
|
| Heart Diseases | 7 | 2019 | 2789 | 0.140 |
Why?
|
| Diarrhea | 3 | 2019 | 1348 | 0.140 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 360 | 0.140 |
Why?
|
| Recurrence | 14 | 2019 | 8340 | 0.140 |
Why?
|
| Cisplatin | 8 | 2010 | 1662 | 0.140 |
Why?
|
| Computer Simulation | 4 | 2018 | 6194 | 0.140 |
Why?
|
| Aromatase | 1 | 2016 | 147 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 4 | 2024 | 1000 | 0.140 |
Why?
|
| Random Allocation | 19 | 1990 | 2428 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 4 | 1999 | 2765 | 0.140 |
Why?
|
| Cyclin D1 | 1 | 2018 | 463 | 0.140 |
Why?
|
| Leukemia, Myeloid | 1 | 1999 | 707 | 0.140 |
Why?
|
| Confidence Intervals | 6 | 2018 | 2971 | 0.130 |
Why?
|
| Endpoint Determination | 2 | 2009 | 601 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 10 | 2015 | 3616 | 0.130 |
Why?
|
| Anthracyclines | 5 | 2019 | 288 | 0.130 |
Why?
|
| Asparaginase | 7 | 2006 | 236 | 0.130 |
Why?
|
| Sex Characteristics | 3 | 2021 | 2585 | 0.120 |
Why?
|
| Estrogen Receptor beta | 1 | 2015 | 175 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 5172 | 0.120 |
Why?
|
| Risk Factors | 43 | 2019 | 72296 | 0.120 |
Why?
|
| Predictive Value of Tests | 15 | 2019 | 15078 | 0.120 |
Why?
|
| Epirubicin | 6 | 2010 | 80 | 0.120 |
Why?
|
| Communication Barriers | 1 | 2017 | 398 | 0.120 |
Why?
|
| Incidence | 16 | 2020 | 20952 | 0.120 |
Why?
|
| Sickness Impact Profile | 1 | 1995 | 302 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1998 | 640 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 1788 | 0.110 |
Why?
|
| Cesarean Section | 3 | 2007 | 1365 | 0.110 |
Why?
|
| International Cooperation | 6 | 2019 | 1420 | 0.110 |
Why?
|
| Aged, 80 and over | 28 | 2021 | 57776 | 0.110 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2018 | 1206 | 0.110 |
Why?
|
| Prednisolone | 8 | 2001 | 334 | 0.110 |
Why?
|
| Decision Support Techniques | 3 | 2012 | 1956 | 0.110 |
Why?
|
| Cognition | 6 | 2016 | 6770 | 0.110 |
Why?
|
| Estradiol | 3 | 2018 | 2020 | 0.110 |
Why?
|
| Mammography | 1 | 2003 | 2475 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2015 | 10943 | 0.100 |
Why?
|
| Risk | 14 | 2019 | 9688 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2013 | 4554 | 0.100 |
Why?
|
| Drug Therapy, Combination | 9 | 2009 | 6489 | 0.100 |
Why?
|
| HIV-1 | 4 | 2007 | 6939 | 0.100 |
Why?
|
| DNA, Neoplasm | 5 | 1997 | 1758 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 1996 | 826 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 8 | 2006 | 1681 | 0.100 |
Why?
|
| Lung Neoplasms | 9 | 2021 | 13104 | 0.100 |
Why?
|
| Carcinoma, Medullary | 1 | 2012 | 123 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2012 | 106 | 0.100 |
Why?
|
| Child, Preschool | 50 | 2012 | 41005 | 0.100 |
Why?
|
| Body Mass Index | 5 | 2012 | 12721 | 0.100 |
Why?
|
| Endocrine System | 2 | 2008 | 113 | 0.100 |
Why?
|
| Dexamethasone | 5 | 2001 | 1951 | 0.100 |
Why?
|
| Receptors, Steroid | 1 | 2011 | 155 | 0.100 |
Why?
|
| Genes, erbB-2 | 2 | 2009 | 162 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2008 | 624 | 0.100 |
Why?
|
| Anti-HIV Agents | 6 | 2004 | 4255 | 0.090 |
Why?
|
| Switzerland | 4 | 2003 | 256 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1038 | 0.090 |
Why?
|
| Patients | 2 | 1995 | 900 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 5223 | 0.090 |
Why?
|
| Early Detection of Cancer | 5 | 2015 | 3086 | 0.090 |
Why?
|
| Health Status Disparities | 2 | 2019 | 1796 | 0.090 |
Why?
|
| Regression Analysis | 6 | 2015 | 6459 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 19905 | 0.090 |
Why?
|
| Rectal Neoplasms | 3 | 1996 | 1205 | 0.090 |
Why?
|
| Self Care | 1 | 1995 | 786 | 0.090 |
Why?
|
| Young Adult | 13 | 2021 | 56429 | 0.090 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2010 | 121 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2015 | 948 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 979 | 0.090 |
Why?
|
| Estrogen Receptor Modulators | 4 | 2012 | 61 | 0.090 |
Why?
|
| Folic Acid | 1 | 2016 | 1300 | 0.090 |
Why?
|
| International Agencies | 3 | 2020 | 240 | 0.080 |
Why?
|
| Melanoma | 4 | 2023 | 5511 | 0.080 |
Why?
|
| Tumor Burden | 4 | 2018 | 1915 | 0.080 |
Why?
|
| Child | 60 | 2012 | 77709 | 0.080 |
Why?
|
| Alkaline Phosphatase | 3 | 2014 | 867 | 0.080 |
Why?
|
| Prospective Studies | 21 | 2023 | 53290 | 0.080 |
Why?
|
| Luteal Phase | 1 | 2009 | 147 | 0.080 |
Why?
|
| Follicular Phase | 1 | 2009 | 153 | 0.080 |
Why?
|
| Retrospective Studies | 29 | 2023 | 77460 | 0.080 |
Why?
|
| Bone Density | 2 | 2014 | 3468 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 1182 | 0.080 |
Why?
|
| Razoxane | 2 | 2006 | 44 | 0.080 |
Why?
|
| Brain Neoplasms | 12 | 1993 | 8861 | 0.080 |
Why?
|
| Hormones | 2 | 2023 | 889 | 0.080 |
Why?
|
| Risk Assessment | 12 | 2019 | 23336 | 0.080 |
Why?
|
| Infant | 37 | 2006 | 35134 | 0.080 |
Why?
|
| Intraoperative Care | 1 | 1992 | 767 | 0.080 |
Why?
|
| Carcinoma in Situ | 3 | 2001 | 806 | 0.080 |
Why?
|
| Cholesterol | 1 | 2017 | 2919 | 0.080 |
Why?
|
| Mass Screening | 2 | 2003 | 5253 | 0.080 |
Why?
|
| Vincristine | 11 | 1997 | 1039 | 0.080 |
Why?
|
| Likelihood Functions | 3 | 2006 | 1005 | 0.080 |
Why?
|
| Self Report | 2 | 2016 | 3553 | 0.080 |
Why?
|
| Leukemia, Lymphoid | 5 | 1986 | 315 | 0.080 |
Why?
|
| Breast Neoplasms, Male | 1 | 2009 | 210 | 0.070 |
Why?
|
| Medication Adherence | 2 | 2016 | 2063 | 0.070 |
Why?
|
| Adolescent | 48 | 2021 | 85779 | 0.070 |
Why?
|
| Interphase | 1 | 1987 | 226 | 0.070 |
Why?
|
| Carcinoma | 3 | 2011 | 2375 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2018 | 7730 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2020 | 3747 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 5534 | 0.070 |
Why?
|
| Premedication | 1 | 2007 | 258 | 0.070 |
Why?
|
| Hot Flashes | 3 | 2016 | 316 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 2134 | 0.070 |
Why?
|
| Medical Oncology | 3 | 2017 | 2267 | 0.070 |
Why?
|
| Analysis of Variance | 9 | 2010 | 6366 | 0.070 |
Why?
|
| Intention to Treat Analysis | 2 | 2021 | 426 | 0.070 |
Why?
|
| Neoplasm Proteins | 3 | 2014 | 3707 | 0.070 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 1149 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 1992 | 3524 | 0.070 |
Why?
|
| Infant, Newborn | 19 | 2007 | 25628 | 0.070 |
Why?
|
| Fertility | 1 | 2011 | 781 | 0.070 |
Why?
|
| Child Behavior | 1 | 1992 | 839 | 0.070 |
Why?
|
| Male | 74 | 2023 | 350115 | 0.070 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 5692 | 0.070 |
Why?
|
| Cytarabine | 8 | 1997 | 692 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 7 | 2015 | 7282 | 0.070 |
Why?
|
| Gene Amplification | 2 | 2009 | 1063 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 8432 | 0.070 |
Why?
|
| Patient Participation | 1 | 2015 | 1457 | 0.070 |
Why?
|
| Adenoma | 1 | 2016 | 2174 | 0.060 |
Why?
|
| Ploidies | 5 | 1994 | 281 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2014 | 2649 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2011 | 788 | 0.060 |
Why?
|
| Multivariate Analysis | 11 | 2012 | 12244 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 1622 | 0.060 |
Why?
|
| Ventricular Function, Left | 4 | 2014 | 3666 | 0.060 |
Why?
|
| Kidney Neoplasms | 3 | 2018 | 4262 | 0.060 |
Why?
|
| Bone Neoplasms | 5 | 2000 | 2530 | 0.060 |
Why?
|
| Aspirin | 1 | 2016 | 3283 | 0.060 |
Why?
|
| Belgium | 1 | 2023 | 103 | 0.060 |
Why?
|
| Eye Diseases | 2 | 2006 | 669 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2002 | 2232 | 0.060 |
Why?
|
| HIV Protease Inhibitors | 2 | 2004 | 430 | 0.060 |
Why?
|
| Odds Ratio | 5 | 2018 | 9849 | 0.060 |
Why?
|
| Vomiting | 2 | 2024 | 637 | 0.060 |
Why?
|
| Biological Assay | 1 | 2006 | 652 | 0.060 |
Why?
|
| Infusions, Intravenous | 4 | 2014 | 2274 | 0.060 |
Why?
|
| Remission Induction | 8 | 2003 | 2385 | 0.060 |
Why?
|
| Longitudinal Studies | 6 | 2016 | 13991 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 3143 | 0.060 |
Why?
|
| Antigens, Neoplasm | 3 | 2010 | 1988 | 0.060 |
Why?
|
| Interferon-alpha | 2 | 1998 | 895 | 0.060 |
Why?
|
| Palliative Care | 7 | 1993 | 3493 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2005 | 2073 | 0.050 |
Why?
|
| Radiotherapy | 10 | 1998 | 1533 | 0.050 |
Why?
|
| Breast | 3 | 2021 | 1970 | 0.050 |
Why?
|
| Fractures, Bone | 3 | 2009 | 1947 | 0.050 |
Why?
|
| Europe | 4 | 2014 | 3338 | 0.050 |
Why?
|
| Sex Factors | 9 | 2019 | 10400 | 0.050 |
Why?
|
| South America | 2 | 2014 | 181 | 0.050 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2003 | 166 | 0.050 |
Why?
|
| Actuarial Analysis | 4 | 1990 | 378 | 0.050 |
Why?
|
| Administration, Oral | 4 | 2015 | 3914 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 3922 | 0.050 |
Why?
|
| Mucin-1 | 1 | 2007 | 543 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 2949 | 0.050 |
Why?
|
| Estrogens | 2 | 2021 | 1566 | 0.050 |
Why?
|
| Urogenital Neoplasms | 1 | 1983 | 137 | 0.050 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2004 | 317 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 772 | 0.050 |
Why?
|
| Cardiovascular Diseases | 4 | 2020 | 15160 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2018 | 710 | 0.050 |
Why?
|
| Heart | 3 | 2004 | 4464 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2016 | 6542 | 0.050 |
Why?
|
| Heart Failure | 5 | 2017 | 10895 | 0.050 |
Why?
|
| Gene Expression | 1 | 1994 | 7798 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2007 | 1872 | 0.050 |
Why?
|
| Nausea | 1 | 2024 | 674 | 0.050 |
Why?
|
| Enalapril | 1 | 2002 | 327 | 0.050 |
Why?
|
| Multiple Sclerosis | 1 | 1995 | 3079 | 0.050 |
Why?
|
| Mutation | 4 | 2024 | 29786 | 0.050 |
Why?
|
| Mathematics | 4 | 1994 | 728 | 0.050 |
Why?
|
| Menstrual Cycle | 2 | 2009 | 551 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2002 | 456 | 0.050 |
Why?
|
| Probability | 7 | 2009 | 2506 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 647 | 0.050 |
Why?
|
| Obesity | 3 | 2012 | 12746 | 0.040 |
Why?
|
| Disease Progression | 5 | 2019 | 13286 | 0.040 |
Why?
|
| Antidiarrheals | 1 | 2019 | 45 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2003 | 671 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 2 | 1996 | 5263 | 0.040 |
Why?
|
| Australia | 2 | 2014 | 1167 | 0.040 |
Why?
|
| Fractures, Spontaneous | 1 | 2001 | 230 | 0.040 |
Why?
|
| Osteonecrosis | 1 | 2001 | 227 | 0.040 |
Why?
|
| Epilepsy | 1 | 1995 | 3310 | 0.040 |
Why?
|
| Troponin T | 1 | 2004 | 754 | 0.040 |
Why?
|
| Fetal Blood | 2 | 2003 | 1318 | 0.040 |
Why?
|
| Inflammation | 1 | 2019 | 10637 | 0.040 |
Why?
|
| North America | 2 | 2014 | 1249 | 0.040 |
Why?
|
| Biometry | 1 | 2002 | 558 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 3799 | 0.040 |
Why?
|
| Algorithms | 2 | 2018 | 13882 | 0.040 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 6773 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2002 | 615 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 2638 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 794 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2024 | 21748 | 0.040 |
Why?
|
| RNA, Viral | 2 | 2004 | 2901 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2000 | 387 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 631 | 0.040 |
Why?
|
| Computer Graphics | 1 | 2000 | 361 | 0.040 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2004 | 623 | 0.040 |
Why?
|
| Adenocarcinoma | 3 | 2008 | 6364 | 0.040 |
Why?
|
| Body Height | 2 | 2003 | 1578 | 0.040 |
Why?
|
| Radiation Injuries | 2 | 2004 | 1180 | 0.040 |
Why?
|
| Radiotherapy Dosage | 11 | 1993 | 2879 | 0.040 |
Why?
|
| Keratins | 1 | 1999 | 515 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2001 | 1461 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2021 | 497 | 0.040 |
Why?
|
| Data Collection | 3 | 1998 | 3339 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 3590 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2021 | 618 | 0.040 |
Why?
|
| Filgrastim | 2 | 2009 | 133 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2004 | 850 | 0.040 |
Why?
|
| Obstetric Labor, Premature | 1 | 1999 | 279 | 0.040 |
Why?
|
| Survivors | 4 | 2017 | 2291 | 0.040 |
Why?
|
| Statistics, Nonparametric | 3 | 2010 | 2887 | 0.040 |
Why?
|
| South Africa | 2 | 2014 | 1731 | 0.040 |
Why?
|
| Cohort Studies | 10 | 2015 | 40559 | 0.040 |
Why?
|
| Thymidylate Synthase | 1 | 1997 | 75 | 0.040 |
Why?
|
| Selection Bias | 1 | 1999 | 371 | 0.040 |
Why?
|
| Treatment Failure | 3 | 2012 | 2618 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 781 | 0.040 |
Why?
|
| Veillonella | 1 | 1977 | 21 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2002 | 820 | 0.040 |
Why?
|
| Internationality | 2 | 2016 | 1002 | 0.040 |
Why?
|
| Aminoglutethimide | 1 | 1996 | 15 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2004 | 1186 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3531 | 0.040 |
Why?
|
| United States | 10 | 2007 | 69872 | 0.040 |
Why?
|
| Logistic Models | 7 | 2014 | 13409 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 15520 | 0.040 |
Why?
|
| Fatigue | 1 | 2024 | 1531 | 0.040 |
Why?
|
| Endocrine Glands | 1 | 1996 | 103 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3921 | 0.030 |
Why?
|
| Hormone Antagonists | 1 | 1996 | 108 | 0.030 |
Why?
|
| Sweating | 1 | 2016 | 123 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2017 | 5077 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 1516 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2011 | 2029 | 0.030 |
Why?
|
| Decision Making | 2 | 2008 | 3888 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2002 | 851 | 0.030 |
Why?
|
| Leucovorin | 2 | 1989 | 628 | 0.030 |
Why?
|
| Software | 1 | 2010 | 4441 | 0.030 |
Why?
|
| Oligopeptides | 2 | 2018 | 1189 | 0.030 |
Why?
|
| Injections, Spinal | 2 | 1993 | 303 | 0.030 |
Why?
|
| AIDS-Related Complex | 1 | 1994 | 110 | 0.030 |
Why?
|
| Patient Selection | 3 | 2015 | 4216 | 0.030 |
Why?
|
| Platinum Compounds | 1 | 2015 | 96 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2009 | 648 | 0.030 |
Why?
|
| Sepsis | 2 | 2000 | 2593 | 0.030 |
Why?
|
| Progestins | 1 | 1996 | 306 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 1998 | 435 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 9647 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2004 | 1714 | 0.030 |
Why?
|
| Interferons | 1 | 1998 | 706 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 610 | 0.030 |
Why?
|
| Age Distribution | 2 | 2016 | 2902 | 0.030 |
Why?
|
| Mycobacterium leprae | 1 | 1993 | 94 | 0.030 |
Why?
|
| Body Weight | 2 | 2003 | 4671 | 0.030 |
Why?
|
| Psychological Tests | 1 | 1996 | 651 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1994 | 803 | 0.030 |
Why?
|
| Interferon-beta | 1 | 1995 | 324 | 0.030 |
Why?
|
| Recombinant Proteins | 4 | 2009 | 6621 | 0.030 |
Why?
|
| Antiviral Agents | 2 | 1996 | 2987 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2014 | 273 | 0.030 |
Why?
|
| Histiocytosis | 1 | 1993 | 40 | 0.030 |
Why?
|
| Postoperative Care | 3 | 2018 | 1487 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2002 | 2047 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 2043 | 0.030 |
Why?
|
| Pectobacterium carotovorum | 1 | 1992 | 6 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 1977 | 402 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 2850 | 0.030 |
Why?
|
| Leukocyte Count | 5 | 1999 | 1588 | 0.030 |
Why?
|
| Nasal Septum | 1 | 1993 | 127 | 0.030 |
Why?
|
| Echocardiography | 5 | 2006 | 5099 | 0.030 |
Why?
|
| Wilms Tumor | 2 | 1987 | 373 | 0.030 |
Why?
|
| Attitude to Health | 3 | 1996 | 2052 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2004 | 1912 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 9445 | 0.030 |
Why?
|
| Bacterial Infections | 2 | 1994 | 1401 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 1999 | 906 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 892 | 0.030 |
Why?
|
| Burkitt Lymphoma | 2 | 2003 | 327 | 0.030 |
Why?
|
| Pregnancy Rate | 1 | 2015 | 643 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 3 | 1988 | 512 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 832 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2001 | 2108 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 1987 | 4034 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 2419 | 0.030 |
Why?
|
| Leprosy, Lepromatous | 1 | 1991 | 23 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2005 | 2758 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3464 | 0.020 |
Why?
|
| Reference Standards | 1 | 1995 | 1025 | 0.020 |
Why?
|
| Cognition Disorders | 2 | 2004 | 4043 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2003 | 3743 | 0.020 |
Why?
|
| New Zealand | 1 | 2011 | 355 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1994 | 657 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 553 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2014 | 592 | 0.020 |
Why?
|
| Mouth Diseases | 1 | 1993 | 241 | 0.020 |
Why?
|
| Uveitis, Anterior | 1 | 1991 | 101 | 0.020 |
Why?
|
| Data Display | 1 | 1991 | 182 | 0.020 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2014 | 386 | 0.020 |
Why?
|
| Maxillofacial Development | 1 | 1990 | 88 | 0.020 |
Why?
|
| Genotype | 2 | 2018 | 12952 | 0.020 |
Why?
|
| Tooth Diseases | 1 | 1990 | 77 | 0.020 |
Why?
|
| Nomograms | 1 | 2012 | 228 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2007 | 7882 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 1799 | 0.020 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1990 | 39 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 652 | 0.020 |
Why?
|
| Central Nervous System Diseases | 2 | 1996 | 518 | 0.020 |
Why?
|
| Fibronectins | 1 | 1993 | 726 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 1151 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 1997 | 1581 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1995 | 783 | 0.020 |
Why?
|
| S Phase | 1 | 1991 | 423 | 0.020 |
Why?
|
| Drug Interactions | 2 | 1992 | 1460 | 0.020 |
Why?
|
| Liposomes | 1 | 2013 | 759 | 0.020 |
Why?
|
| Self-Evaluation Programs | 1 | 1989 | 29 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1994 | 1364 | 0.020 |
Why?
|
| Denmark | 1 | 2011 | 738 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4185 | 0.020 |
Why?
|
| Integrins | 1 | 1993 | 846 | 0.020 |
Why?
|
| Lectins | 1 | 1991 | 513 | 0.020 |
Why?
|
| Preoperative Care | 5 | 2009 | 2251 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2460 | 0.020 |
Why?
|
| Glioma | 1 | 2004 | 3401 | 0.020 |
Why?
|
| Androgens | 1 | 1996 | 1281 | 0.020 |
Why?
|
| Acute Disease | 1 | 1999 | 7147 | 0.020 |
Why?
|
| Lymphocyte Depletion | 2 | 1990 | 608 | 0.020 |
Why?
|
| Comorbidity | 3 | 2013 | 10388 | 0.020 |
Why?
|
| Cerebellar Neoplasms | 1 | 1993 | 587 | 0.020 |
Why?
|
| ras Proteins | 1 | 2013 | 1060 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2725 | 0.020 |
Why?
|
| Papilloma | 1 | 1988 | 148 | 0.020 |
Why?
|
| Tracheal Neoplasms | 1 | 1988 | 124 | 0.020 |
Why?
|
| Medulloblastoma | 1 | 1993 | 683 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2002 | 2560 | 0.020 |
Why?
|
| Necrosis | 2 | 2009 | 1643 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 1990 | 647 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1994 | 1434 | 0.020 |
Why?
|
| Nails | 1 | 2009 | 292 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1990 | 547 | 0.020 |
Why?
|
| Blindness | 1 | 1991 | 615 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 1998 | 547 | 0.020 |
Why?
|
| Nitrous Oxide | 1 | 1987 | 176 | 0.020 |
Why?
|
| Cost of Illness | 1 | 1996 | 1860 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1994 | 5181 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 6313 | 0.020 |
Why?
|
| Viral Load | 2 | 2007 | 3300 | 0.020 |
Why?
|
| Bone Marrow Cells | 2 | 2001 | 2513 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1692 | 0.020 |
Why?
|
| Bone Marrow | 4 | 1999 | 2948 | 0.020 |
Why?
|
| Sulfamethoxazole | 1 | 1985 | 53 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 1252 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2000 | 627 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 3 | 1987 | 2736 | 0.020 |
Why?
|
| Trimethoprim | 1 | 1985 | 91 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1993 | 1415 | 0.020 |
Why?
|
| Sigmoid Neoplasms | 1 | 1985 | 51 | 0.020 |
Why?
|
| Radiography | 1 | 1996 | 7023 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 1995 | 1916 | 0.020 |
Why?
|
| Complement System Proteins | 2 | 1986 | 795 | 0.020 |
Why?
|
| Arm | 2 | 1980 | 589 | 0.020 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 1980 | 277 | 0.020 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 3611 | 0.020 |
Why?
|
| Escherichia coli | 2 | 1999 | 4217 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2002 | 5135 | 0.020 |
Why?
|
| Osteosarcoma | 2 | 1995 | 881 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1988 | 542 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2014 | 1579 | 0.020 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 10183 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2003 | 876 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 1992 | 1425 | 0.010 |
Why?
|
| Central Nervous System | 2 | 2002 | 1357 | 0.010 |
Why?
|
| Daunorubicin | 3 | 1990 | 158 | 0.010 |
Why?
|
| Bahamas | 1 | 2003 | 11 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1983 | 101 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1992 | 884 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 535 | 0.010 |
Why?
|
| Methods | 1 | 1983 | 1129 | 0.010 |
Why?
|
| Health Status | 2 | 2012 | 4034 | 0.010 |
Why?
|
| Patient Compliance | 2 | 2008 | 2684 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 1991 | 2307 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 380 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 163 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3154 | 0.010 |
Why?
|
| Immunophenotyping | 2 | 1999 | 1880 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 6171 | 0.010 |
Why?
|
| Bacterial Proteins | 2 | 1993 | 3854 | 0.010 |
Why?
|
| Prevalence | 2 | 2016 | 15221 | 0.010 |
Why?
|
| Fibrosis | 1 | 2009 | 2029 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 3595 | 0.010 |
Why?
|
| Abortion, Spontaneous | 1 | 2007 | 544 | 0.010 |
Why?
|
| Phenanthridines | 1 | 1981 | 51 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 2 | 1998 | 651 | 0.010 |
Why?
|
| Eye | 1 | 2006 | 729 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15535 | 0.010 |
Why?
|
| Peptides | 1 | 2014 | 4410 | 0.010 |
Why?
|
| Age of Onset | 2 | 2001 | 3270 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 4328 | 0.010 |
Why?
|
| Attention | 1 | 1992 | 2397 | 0.010 |
Why?
|
| Karyotyping | 2 | 1996 | 1243 | 0.010 |
Why?
|
| Organizational Policy | 1 | 2003 | 429 | 0.010 |
Why?
|
| Visual Acuity | 2 | 2006 | 2530 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1990 | 1352 | 0.010 |
Why?
|
| Esophageal Neoplasms | 2 | 1980 | 1585 | 0.010 |
Why?
|
| Semustine | 3 | 1985 | 11 | 0.010 |
Why?
|
| Liver | 2 | 2012 | 7475 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 1620 | 0.010 |
Why?
|
| Diastole | 1 | 2002 | 791 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2001 | 403 | 0.010 |
Why?
|
| Intelligence Tests | 2 | 1992 | 505 | 0.010 |
Why?
|
| Emotions | 1 | 1992 | 2659 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1985 | 1125 | 0.010 |
Why?
|
| Antiemetics | 1 | 1981 | 177 | 0.010 |
Why?
|
| Flow Cytometry | 2 | 1987 | 5974 | 0.010 |
Why?
|
| Life Tables | 2 | 1990 | 370 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1983 | 604 | 0.010 |
Why?
|
| Morbidity | 1 | 2005 | 1768 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 1983 | 379 | 0.010 |
Why?
|
| Bleomycin | 1 | 1980 | 512 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2005 | 1530 | 0.010 |
Why?
|
| Socioeconomic Factors | 3 | 2001 | 7785 | 0.010 |
Why?
|
| Teniposide | 1 | 1998 | 10 | 0.010 |
Why?
|
| Brazil | 1 | 2003 | 1270 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 2002 | 333 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1985 | 934 | 0.010 |
Why?
|
| Renal Dialysis | 2 | 1980 | 1783 | 0.010 |
Why?
|
| Gestational Age | 1 | 2007 | 3493 | 0.010 |
Why?
|
| Brachial Artery | 2 | 1980 | 369 | 0.010 |
Why?
|
| Phenotype | 2 | 1994 | 16367 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2005 | 8551 | 0.010 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2000 | 232 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1997 | 12207 | 0.010 |
Why?
|
| Myocardial Contraction | 2 | 1995 | 1579 | 0.010 |
Why?
|
| Apoptosis | 1 | 1994 | 9724 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 4982 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1983 | 1608 | 0.010 |
Why?
|
| Internet | 1 | 2010 | 3056 | 0.010 |
Why?
|
| Forecasting | 2 | 1998 | 2951 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2000 | 341 | 0.010 |
Why?
|
| SEER Program | 1 | 2002 | 1507 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 1405 | 0.010 |
Why?
|
| Transplantation, Autologous | 2 | 1993 | 2124 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1996 | 256 | 0.010 |
Why?
|
| Sleep | 1 | 1992 | 4622 | 0.010 |
Why?
|
| Etoposide | 2 | 1992 | 641 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2002 | 1086 | 0.010 |
Why?
|
| Prejudice | 1 | 2000 | 570 | 0.010 |
Why?
|
| Foot Diseases | 1 | 1977 | 143 | 0.010 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 1997 | 345 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1996 | 203 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1980 | 1663 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2002 | 18111 | 0.010 |
Why?
|
| AIDS Dementia Complex | 1 | 1996 | 154 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 1851 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2011 | 3751 | 0.010 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 1997 | 294 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2002 | 1275 | 0.010 |
Why?
|
| Thailand | 1 | 1995 | 296 | 0.010 |
Why?
|
| Cellulitis | 1 | 1977 | 206 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1995 | 187 | 0.010 |
Why?
|
| Phylogeny | 1 | 2002 | 2804 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4751 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 1995 | 240 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2002 | 1541 | 0.010 |
Why?
|
| Sputum | 1 | 1976 | 476 | 0.010 |
Why?
|
| Self-Assessment | 1 | 1996 | 390 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1990 | 4839 | 0.010 |
Why?
|
| Leprosy | 1 | 1993 | 124 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2006 | 3817 | 0.010 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 1997 | 670 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 5953 | 0.010 |
Why?
|
| Social Class | 1 | 2002 | 1997 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2001 | 1928 | 0.010 |
Why?
|
| Diseases in Twins | 1 | 1994 | 449 | 0.010 |
Why?
|
| Stem Cells | 1 | 2006 | 3567 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 1680 | 0.010 |
Why?
|
| Depression | 1 | 1992 | 7759 | 0.010 |
Why?
|
| Solubility | 1 | 1993 | 1088 | 0.010 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 1990 | 24 | 0.010 |
Why?
|
| Neuropsychological Tests | 2 | 1996 | 6994 | 0.010 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1990 | 40 | 0.010 |
Why?
|
| Odontogenesis | 1 | 1990 | 66 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12797 | 0.010 |
Why?
|
| Mastectomy, Simple | 1 | 1990 | 24 | 0.010 |
Why?
|
| Phenylephrine | 1 | 1991 | 301 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1995 | 792 | 0.010 |
Why?
|
| Tooth Root | 1 | 1990 | 165 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1991 | 623 | 0.010 |
Why?
|
| Azacitidine | 1 | 1992 | 347 | 0.010 |
Why?
|
| Liver Neoplasms | 2 | 1986 | 4253 | 0.010 |
Why?
|
| Postoperative Complications | 5 | 1987 | 15297 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1993 | 530 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 25039 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1983 | 2282 | 0.010 |
Why?
|
| Remission, Spontaneous | 2 | 1980 | 382 | 0.010 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1976 | 810 | 0.010 |
Why?
|
| Philadelphia Chromosome | 1 | 1989 | 112 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2002 | 3112 | 0.010 |
Why?
|
| Epithelium | 1 | 1993 | 1679 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1981 | 2214 | 0.010 |
Why?
|
| Infant, Premature, Diseases | 1 | 1994 | 707 | 0.010 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 215 | 0.000 |
Why?
|
| Boston | 1 | 2001 | 9312 | 0.000 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1991 | 585 | 0.000 |
Why?
|
| Thioguanine | 1 | 1987 | 46 | 0.000 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1990 | 281 | 0.000 |
Why?
|
| Models, Biological | 1 | 1983 | 9584 | 0.000 |
Why?
|
| Intelligence | 1 | 1992 | 920 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1989 | 514 | 0.000 |
Why?
|
| Ligands | 1 | 1993 | 3282 | 0.000 |
Why?
|
| Naphthacenes | 1 | 1986 | 7 | 0.000 |
Why?
|
| Placebos | 1 | 1990 | 1676 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1994 | 2617 | 0.000 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 1986 | 136 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1983 | 5181 | 0.000 |
Why?
|
| Suspensions | 1 | 1985 | 65 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 17446 | 0.000 |
Why?
|
| Cobalt Radioisotopes | 1 | 1985 | 76 | 0.000 |
Why?
|
| Fetal Death | 1 | 1987 | 448 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1985 | 356 | 0.000 |
Why?
|
| Hospitalization | 1 | 2004 | 10259 | 0.000 |
Why?
|
| Pilot Projects | 2 | 1991 | 8319 | 0.000 |
Why?
|
| Translocation, Genetic | 1 | 1989 | 1420 | 0.000 |
Why?
|
| Neprilysin | 1 | 1986 | 439 | 0.000 |
Why?
|
| Veins | 2 | 1980 | 770 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1983 | 318 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1986 | 980 | 0.000 |
Why?
|
| Exercise Test | 1 | 1991 | 2073 | 0.000 |
Why?
|
| Chromosome Aberrations | 1 | 1989 | 1813 | 0.000 |
Why?
|
| Tomography, Emission-Computed | 1 | 1986 | 1144 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1985 | 2255 | 0.000 |
Why?
|
| Infant, Low Birth Weight | 1 | 1987 | 850 | 0.000 |
Why?
|
| Thyroid Function Tests | 1 | 1983 | 286 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1995 | 5984 | 0.000 |
Why?
|
| Medicare | 1 | 2000 | 6566 | 0.000 |
Why?
|
| Infant Mortality | 1 | 1987 | 754 | 0.000 |
Why?
|
| Aging | 1 | 2001 | 8664 | 0.000 |
Why?
|
| Maximum Allowable Concentration | 1 | 1981 | 62 | 0.000 |
Why?
|
| Cataract | 1 | 1988 | 834 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13814 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1993 | 3690 | 0.000 |
Why?
|
| Protein Binding | 1 | 1993 | 9384 | 0.000 |
Why?
|
| Abscess | 1 | 1985 | 607 | 0.000 |
Why?
|
| Clone Cells | 1 | 1985 | 1692 | 0.000 |
Why?
|
| Intestinal Obstruction | 1 | 1985 | 423 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1994 | 4386 | 0.000 |
Why?
|
| Streptozocin | 1 | 1981 | 196 | 0.000 |
Why?
|
| Abdomen | 1 | 1987 | 1118 | 0.000 |
Why?
|
| Stereoisomerism | 1 | 1981 | 624 | 0.000 |
Why?
|
| Hypopharynx | 1 | 1980 | 52 | 0.000 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1980 | 117 | 0.000 |
Why?
|
| Injections, Intramuscular | 1 | 1981 | 552 | 0.000 |
Why?
|
| Graft Survival | 1 | 1990 | 3737 | 0.000 |
Why?
|
| Rabbits | 1 | 1986 | 4894 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1985 | 1958 | 0.000 |
Why?
|
| Immune Sera | 1 | 1980 | 641 | 0.000 |
Why?
|
| Oropharynx | 1 | 1980 | 127 | 0.000 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1980 | 228 | 0.000 |
Why?
|
| Cause of Death | 1 | 1990 | 3582 | 0.000 |
Why?
|
| Cell Line | 1 | 1993 | 16000 | 0.000 |
Why?
|
| Abdominal Neoplasms | 1 | 1981 | 292 | 0.000 |
Why?
|
| Thrombophlebitis | 1 | 1980 | 309 | 0.000 |
Why?
|
| Melphalan | 1 | 1981 | 431 | 0.000 |
Why?
|
| Cell Separation | 1 | 1985 | 1751 | 0.000 |
Why?
|
| Macrophages | 1 | 1993 | 5660 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1981 | 420 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1980 | 471 | 0.000 |
Why?
|
| Extremities | 1 | 1984 | 866 | 0.000 |
Why?
|
| Neurologic Examination | 1 | 1981 | 931 | 0.000 |
Why?
|
| Stroke Volume | 1 | 1991 | 5006 | 0.000 |
Why?
|
| Myocardium | 1 | 1991 | 4772 | 0.000 |
Why?
|
| Wound Infection | 1 | 1980 | 242 | 0.000 |
Why?
|
| Infant, Premature | 1 | 1987 | 2045 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1986 | 2133 | 0.000 |
Why?
|
| Arteriovenous Fistula | 1 | 1980 | 315 | 0.000 |
Why?
|
| Embolism | 1 | 1980 | 408 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1991 | 9145 | 0.000 |
Why?
|
| Cerebral Angiography | 1 | 1981 | 1285 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1983 | 1173 | 0.000 |
Why?
|
| Anesthesia | 1 | 1987 | 1561 | 0.000 |
Why?
|
| Long-Term Care | 1 | 1980 | 607 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1980 | 2505 | 0.000 |
Why?
|
| Animals | 2 | 2003 | 168768 | 0.000 |
Why?
|
| Reoperation | 1 | 1985 | 4201 | 0.000 |
Why?
|
| Mouth Neoplasms | 1 | 1980 | 601 | 0.000 |
Why?
|
| Headache | 1 | 1981 | 1226 | 0.000 |
Why?
|
| Motor Activity | 1 | 1981 | 2715 | 0.000 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1980 | 1856 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1980 | 2708 | 0.000 |
Why?
|
| Kidney Failure, Chronic | 1 | 1980 | 2535 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1981 | 6151 | 0.000 |
Why?
|
| Brain | 1 | 1992 | 26388 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1980 | 12961 | 0.000 |
Why?
|